The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …

BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …

Background The incidence of brain metastases (BM) in melanoma patients is common and
associated with poor prognosis. MAP-kinase inhibitors and immunologic checkpoint …

Background Historically, the prognosis for patients who have melanoma brain metastasis
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …

Background Despite of various therapeutic strategies, treatment of patients with melanoma
brain metastasis (MBM) still is a major challenge. This study aimed at investigating the …

Background The impact of the order of treatment with checkpoint inhibitors or BRAF/MEK
inhibitors on the development of brain metastases in patients with metastatic unresectable …

Background Immune checkpoint blockade has systemic efficacy in patients with metastatic
melanoma, including those with brain metastases (MBMs). However, immunotherapy …

Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …

Immune checkpoints restrain the immune system following its activation and their inhibition
unleashes anti-tumor immune responses. Immune checkpoint inhibitors revolutionized the …

Background Despite the availability of effective systemic therapies, a significant number of
advanced melanoma patients develops brain metastases. This study investigated …